Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
130 hedge funds and large institutions have $1.53B invested in Mersana Therapeutics in 2020 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 51 increasing their positions, 22 reducing their positions, and 6 closing their positions.
800% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 6
556% more capital invested
Capital invested by funds: $234M → $1.53B (+$1.3B)
530% more call options, than puts
Call options by funds: $8.5M | Put options by funds: $1.35M
132% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 22
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
59% more funds holding
Funds holding: 82 → 130 (+48)
0.38% more ownership
Funds ownership: 3.53% → 3.91% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$88.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$80.5M |
| 3 |
BlackRock
New York
|
+$52.6M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$47.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$54.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$18.8M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$16.1M |
| 4 |
VA
VR Adviser
New York
|
-$15.3M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$13.8M |
MRSN Hedge Fund Activity: Q2 2020 in Review
130 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2020, worth a combined $1.53B — up 556% from $234M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new MRSN positions and 6 closed out — a net gain of 48 holders — while 51 added to existing stakes and 22 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $88.8M. The largest seller was NEA Management Company, cutting an estimated $54.7M.
- 130 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2020, up from 82 in Q1 2020.
- Funds reported $1.53B of Mersana Therapeutics stock for Q2 2020, up 556% quarter-over-quarter.
- 54 funds opened new Mersana Therapeutics positions in Q2 2020 and 6 closed out, a net change of +48 holders.
- The largest Mersana Therapeutics buyer in Q2 2020 was Avoro Capital Advisors, an estimated $88.8M added.
- The largest Mersana Therapeutics seller in Q2 2020 was NEA Management Company, an estimated $54.7M sold.
Based on aggregated 13F filings for Q2 2020.